Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

Fig. 4

Effect of MEDI-551 on peripheral B cells. Median B cell counts over time, by MEDI-551 dose. B cell counts are presented as % of day 1 values. The data plotted represent only those subjects for which B cell counts are available at each time point. The number of subjects in the analysis in each group at each time point is tabulated below the graph. This number declines over time as subjects exit the study following B cell repletion

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us